aggressive!mantle>cell!lymphoma.!Journal!of!clinical!oncology!:!official!journal!of!the!American!
Society!of!Clinical!Oncology.!1998;16(12):3803>9.!
3.!Geisler!CH,!Kolstad!A,!Laurell!A,!Andersen!NS,!Pedersen!LB,!Jerkeman!M,!et!al.!Long>term!
progression>free!survival!of!mantle!cell!lymphoma!after!intensive!front>line!immunochemotherapy!
with!in!vivo>purged!stem!cell!rescue:!a!nonrandomized!phase!2!multicenter!study!by!the!Nordic!
Lymphoma!Group.!Blood.!2008;112(7):2687>93.!
4.!Hermine!O,!Hoster!E,!Walewski!J,!Bosly!A,!Stilgenbauer!S,!Thieblemont!C,!et!al.!Addition!of!high>
dose!cytarabine!to!immunochemotherapy!before!autologous!stem>cell!transplantation!in!patients!
aged!65!years!or!younger!with!mantle!cell!lymphoma!(MCL!Younger):!a!randomised,!open>label,!
phase!3!trial!of!the!European!Mantle!Cell!Lymphoma!Network.!Lancet.!2016;388(10044):565>75.!
5.!Le!Gouill!S,!Thieblemont!C,!Oberic!L,!Moreau!A,!Bouabdallah!K,!Dartigeas!C,!et!al.!Rituximab!after!
Autologous!Stem>Cell!Transplantation!in!Mantle>Cell!Lymphoma.!The!New!England!journal!of!
medicine.!2017;377(13):1250>60.!
6.!Gerson!JN,!Handorf!E,!Villa!D,!Gerrie!AS,!Chapani!P,!Li!S,!et!al.!Survival!Outcomes!of!Younger!
Patients!With!Mantle!Cell!Lymphoma!Treated!in!the!Rituximab!Era.!Journal!of!clinical!oncology!:!
official!journal!of!the!American!Society!of!Clinical!Oncology.!2019;37(6):471>80.!
7.!Freedman!AS,!Neuberg!D,!Gribben!JG,!Mauch!P,!Soiffer!RJ,!Fisher!DC,!et!al.!High>dose!
chemoradiotherapy!and!anti>B>cell!monoclonal!antibody>purged!autologous!bone!marrow!
transplantation!in!mantle>cell!lymphoma:!no!evidence!for!long>term!remission.!Journal!of!clinical!
oncology!:!official!journal!of!the!American!Society!of!Clinical!Oncology.!1998;16(1):13>8.!
8.!Dreyling!M,!Lenz!G,!Hoster!E,!Van!Hoof!A,!Gisselbrecht!C,!Schmits!R,!et!al.!Early!consolidation!by!
myeloablative!radiochemotherapy!followed!by!autologous!stem!cell!transplantation!in!first!remission!
significantly!prolongs!progression>!free!survival!in!mantle>cell!lymphoma:!results!of!a!prospective!
randomized!trial!of!the!European!MCL!Network.!Blood.!2005;105(7):2677>84.!
9.!Eskelund!CW,!Kolstad!A,!Jerkeman!M,!Raty!R,!Laurell!A,!Eloranta!S,!et!al.!15>year!follow>up!of!the!
Second!Nordic!Mantle!Cell!Lymphoma!trial!(MCL2):!prolonged!remissions!without!survival!plateau.!Br!
J!Haematol.!2016;175(3):410>8.!
10.!Kluin>Nelemans!HC,!Hoster!E,!Hermine!O,!Walewski!J,!Trneny!M,!Geisler!CH,!et!al.!Treatment!of!
Older!Patients!with!Mantle>Cell!Lymphoma.!New!England!Journal!of!Medicine.!2012;367(6):520>31.!
11.!Romaguera!JE,!Fayad!L,!Rodriguez!MA,!Broglio!KR,!Hagemeister!FB,!Pro!B,!et!al.!High!rate!of!
durable!remissions!after!treatment!of!newly!diagnosed!aggressive!mantle>cell!lymphoma!with!
rituximab!plus!hyper>CVAD!alternating!with!rituximab!plus!high>dose!methotrexate!and!cytarabine.!
Journal!of!clinical!oncology!:!official!journal!of!the!American!Society!of!Clinical!Oncology.!
2005;23(28):7013>23.!
12.!Visco!C,!Chiappella!A,!Nassi!L,!Patti!C,!Ferrero!S,!Barbero!D,!et!al.!Rituximab,!bendamustine,!and!
low>dose!cytarabine!as!induction!therapy!in!elderly!patients!with!mantle!cell!lymphoma:!a!
multicentre,!phase!2!trial!from!Fondazione!Italiana!Linfomi.!Lancet!Haematol.!2017;4(1):e15>e23.!
13.!Frosch!Z,!Luskin!MR,!Landsburg!DJ,!Schuster!SJ,!Svoboda!J,!Loren!AW,!et!al.!R>CHOP!or!R>
HyperCVAD!with!or!without!autologous!stem!cell!transplantation!for!older!patients!with!mantle!cell!
lymphoma.!Clin!Lymphoma!Myeloma!Leuk.!2015;15(2):92>7.!
14.!Robak!T,!Jin!J,!Pylypenko!H,!Verhoef!G,!Siritanaratkul!N,!Drach!J,!et!al.!Frontline!bortezomib,!
rituximab,!cyclophosphamide,!doxorubicin,!and!prednisone!(VR>CAP)!versus!rituximab,!
cyclophosphamide,!doxorubicin,!vincristine,!and!prednisone!(R>CHOP)!in!transplantation>ineligible!
patients!with!newly!diagnosed!mantle!cell!lymphoma:!final!overall!survival!results!of!a!randomised,!
open>label,!phase!3!study.!Lancet!Oncol.!2018;19(11):1449>58.!
15.!Eskelund!CW,!Dahl!C,!Hansen!JW,!Westman!M,!Kolstad!A,!Pedersen!LB,!et!al.!TP53!mutations!
identify!younger!mantle!cell!lymphoma!patients!who!do!not!benefit!from!intensive!
chemoimmunotherapy.!Blood.!2017;130(17):1903>10.!16.!Hoster!E,!Pott!C.!Minimal!residual!disease!
in!mantle!cell!lymphoma:!insights!into!biology!and!impact!on!treatment.!Hematology!Am!Soc!
Hematol!Educ!Program.!2016;2016(1):437>45.!
17.!Lenz!G,!Hiddemann!W,!Dreyling!M.!The!role!of!fludarabine!in!the!treatment!of!follicular!and!
mantle!cell!lymphoma.!Cancer.!2004;101(5):883>93.!!
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES